Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

Translational Research

Volumn 149, Issue 3, 2007, Pages 114-125

  Miele, Luca ^a   Forgione, Alessandra ^a   Gasbarrini, Giovanni ^a   Grieco, Antonio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER;

DISEASE COURSE; HEREDITY; HIGH RISK PATIENT; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; FATTY LIVER; FIBROSIS; HEPATITIS; HUMANS; RISK FACTORS;

EID: 33847058521     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.11.011     Document Type: Review

References (122)

1. Neuschwander-Tetri B.A., and Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatol 37 (2003) 1202-1219
2. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., and Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatol 42 (2005) 44-52
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346 (2002) 1221-1231
4. Di Bisceglie A.M., Lyra A.C., Schwartz M., Reddy R.K., Martin P., Gores G., et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 98 (2003) 2060-2063
5. Ratziu V., Giral P., Charlotte F., Bruckert E., Thibault V., Theodorou I., et al. Liver fibrosis in overweight patients. Gastroenterology 118 (2000) 1117-1123
6. De Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., and Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 22 (1999) 756-761
7. Reeves H.L., and Friedman S.L. Activation of hepatic stellate cells-a key issue in liver fibrosis. Front Biosci 7 (2002) d808-d826
8. Leclerque I.A. Antioxidant defence mechanisms: new players in the pathogenesis of non-alcoholic steatohepatitis?. Clin Sci 106 (2004) 235-237
9. Day C.P., and James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterol 114 (1998) 842-845
10. Miele L., Forgione A., Hernandez A.P., Gabrieli M.L., Vero V., Di Rocco P., et al. The natural history and risk factors for progression of non-alcoholic fatty liver disease and steatohepatitis. Eur Rev Med Pharmacol Sci 9 (2005) 273-278
11. Yahagi N., Shimano H., Hasty A.H., Matsuzaka T., Ide T., Yoshikawa T., et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 277 (2002) 19353-19357
12. Charlton M., Sreekumar R., Rasmussen D., Lindor K., and Nair K.S. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatol 35 (2002) 898-904
13. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., and Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115 (2005) 1343-1351
14. Miele L., Grieco A., Armuzzi A., Candelli M., Forgione A., Gasbarrini A., et al. Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test. Am J Gastroenterol 98 (2003) 2335-2336
15. Pessayre D., and Fromenty B. NASH: a mitochondrial disease. J Hepatol 42 (2005) 928-940
16. Day C.P. Non-alcoholic fatty liver disease: current concepts and management strategies. Clin Med 6 (2006) 19-25
17. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterol 120 (2001) 1183-1192
18. Choudhury J., and Sanyal A.J. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004) 575-594 ix
19. Weltman M.D., Farrell G.C., Hall P., Ingelman-Sundberg M., and Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatol 27 (1998) 128-133
20. Leclercq I.A., Farrell G.C., Field J., Bell D.R., Gonzalez F.J., and Robertson G.R. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 105 (2000) 1067-1075
21. Pessayre D., Mansouri A., and Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol 282 (2002) G193-G199
22. Albano E., Mottaran E., Vidali M., Reale E., Saksena S., Occhino G., et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut 54 (2005) 987-993
23. Marra F., Aleffi S., Bertolani C., Petrai I., and Vizzuti F. Adipokines and liver fibrosis. Eur Rev Med Pharmacol Sci 9 (2005) 279-284
24. Nieto N., Friedman S.L., and Caderbaum A.I. Stimulation and production of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology 35 (2002) 62-73
25. Bedossa P., Houglum K., Trautwein C., Holstege A., and Chojkier M. Stimulation of collagen alpha I gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis?. Hepatology 194 (1994) 1044-1050
26. Paradis V., Perlemuter G., Bonvoust F., Dargere D., Parfait B., Vidaud M., et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 34 (2001) 738-744
27. Angulo P., Keach J.C., Batts K.P., and Lindor K. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 30 (1999) 1356-1362
28. Dixon J.B., Bhathal P.S., and O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121 (2001) 91-100
29. Ryan M.C., Wilson A.M., Slavin J., Best J.D., Jenkins A.J., and Desmond P.V. Associations Between liver histology and severity of the Metabolic Syndrome in subjects with Nonalcoholic Fatty Liver Disease. Diabetes Care 28 (2005) 1222-1224
30. Bugianesi E., Manzini P., D'Antico S., Vanni E., Longo F., Leone N., et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39 (2004) 1749-1787
31. Abrams G.A., Kunde S.S., Lazenby A.J., and Clements R.H. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. Hepatology 40 (2004) 475-483
32. Palekar N.A., Naus R., Larson S.P., Ward J., and Harrison S.A. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 26 (2006) 151-156
33. Loguercio C., De Simone T., D'Auria M.V., de Sio I., Federico A., Tuccillo C., et al. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig Liver Dis 36 (2004) 398-405
34. Yesilova Z., Yaman H., Oktenli C., Ozcan A., Uygun A., Cakir E., et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 100 (2005) 850-855
35. Harrison S.A., Torgerson S., and Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98 (2003) 2042-2047
36. Adams L.A., Sanderson S., Lindor K.D., and Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42 (2005) 132-138
37. Fassio E., Alvarez E., Dominguez N., Landeira G., and Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40 (2004) 820-826
38. Wanless I.R., and Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12 (1990) 1106-1110
39. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., and McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116 (1999) 1413-1419
40. Garcia-Monzon C., Martin-Perez E., Iacono O.L., Fernandez-Bermejo M., Majano P.L., et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 33 (2000) 716-724
41. McCullough A.J. Strategies for the evaluation of nonalcoholic steatohepatitis. In: Arroyo V., Navata M., Forns X., Bataller R., Sanchez-Fueyo A., and Rodes J. (Eds). Update in treatment of liver disease (2005), Grupo Ars XXI de comunication SL, Barcelona, Spain 303-310
42. Mofrad P., Contos M.J., Haque M., Sargeant C., Fisher R.A., Luketic V.A., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatol 37 (2003) 1286-1292
43. Afdhal N.H., and Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 99 (2004) 1160-1174
44. Campbell M.S., and Reddy K.R. Review article: the evolving role of liver biopsy. Aliment Pharmacol Ther 20 (2004) 249-259
45. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatol 38 (2003) 1449-1457
46. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005) 1898-1906
47. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterolpgy 123 (2002) 745-750
48. Hamaguchi M., Kojima T., Takeda N., Nakagawa T., Taniguchi H., Fujii K., et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143 (2005) 722-728
49. Pinzani M., Rombouts K., and Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 42 suppl 1 (2005) S22-S36
50. Ataseven H., Yildirim M.H., Yalniz M., Bahcecioglu I.H., Celebi S., and Ozercan I.H. The value of ultrasonography and computerized tomography in estimating the histopathological severity of nonalcoholic steatohepatitis. Acta Gastroenterol Belg 68 (2005) 221-225
51. Fishbein M., Castro F., Cheruku S., Jain S., Webb B., Gleason T., et al. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 39 (2005) 619-625
52. Szczepaniak L.S., Nurenberg P., Leonard D., Browning J.D., Reingold J.S., Grundy S., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288 (2005) E462-E468
53. Sandrin L., Fourquet B., Hasquenoph J.M., Yon S., Fournier C., Mal F., et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29 (2003) 1705-1713
54. Castera L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Haaser M., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterol 128 (2005) 343-350
55. Dam-Larsen S., Franzmann M., Andersen I.B., Christoffersen P., Jensen L.B., Sorensen T.I., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53 (2004) 750-755
56. Teli M.R., James O.F., Burt A.D., Bennett M.K., and Day C.P. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatol 22 (1995) 1714-1719
57. Harrison S.A., Torgerson S., and Hayashi P.H. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98 (2003) 2042-2047
58. Clark J.M., Brancati F.L., and Diehl A.M. Nonalcoholic fatty liver disease. Gastroenterology 122 (2002) 1649-1657
59. Reid A.E. Nonalcoholic steatohepatitis. Gastroenterol 121 (2001) 710-723
60. te Sligte K., Bourass I., Sels J.P., Driessen A., Stockbru Ugger R.W., et al. Non-alcoholic steatohepatitis: review of a growing medical problem. Eur J Internal Med 15 (2004) 10-21
61. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123 (2002) 134-140
62. Marrero J.A., Fontana R.J., Su G.L., Conjeevaram H.S., Emick D.M., and Lok A.S. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatol 36 (2002) 1349-1354
63. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al., Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for Nonalcoholic Fatty Liver Disease. Hepatol 41 (2005) 1313-1321
64. Ratziu V., and Poynard T. NASH: a hidden fibroser finally revealed?. J Hepatol 42 (2005) 12-14
65. Bugianesi E., Zannoni C., Vanni E., Marzocchi R., and Marchesini G. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?. Dig Liver Dis 36 (2004) 165-173
66. Friedman SL. The cellular basis of hepatic fibrosis: mechanisms and treatment strategies. N Engl J Med 328:1828-35.
67. Friedman S.L. Cytokines and fibrogenesis. Semin Liver Dis 19 (1999) 129-140
68. Geerts A. History, heterogeneity developmental biology and functions of quiescent hepatic stellate cells. Seminars Liver Dis 21 (2001) 311-337
69. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterol 120 (2001) 1183-1192
70. Seki S., Kitada T., Yamada T., Sakaguchi H., Nakatani K., and Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol 37 (2002) 56-62
71. Van Zee K.J., Kohno T., Fischer E., Rock C.S., Moldawer L.L., and Lowry S.F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci USA 89 (1992) 4845-4849
72. Zylberberg H., Rimaniol A.C., Pol S., Masson A., De Groote D., Berthelot P., et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 30 (1999) 185-191
73. Crespo J., Cayon A., Fernandez-Gil P., Hernandez-Guerra M., Mayorga M., Dominguez-Diez A., Fernandez-Escalante J.C., and Pons-Romero F. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatol 34 (2001) 1158-1163
74. Reeves H.L., and Friedman S.L. Activation of hepatic stellate cells-a key issue in liver fibrosis. Front Biosci 7 (2002) d808-d826
75. Olaso E., and Friedman S.L. Molecular regulation of hepatic fibrogenesis. J Hepatol 29 (1998) 836-847
76. Gressner A.M., and Bachem M.G. Molecular mechanisms of liver fibrogenesis - a homage to the role of activated fat-storing cells. Digestion 56 (1995) 335-346
77. Edwards D., Murphy G., Reynolds J., Whitham S., Docherty A., Angel P., et al. TGF beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 6 (1987) 1899-1904
78. De Bleser P.J., Niki T., Rogiers V., and Geerts A. J Hepatol 26 (1997) 886-893
79. Castilla A., Prieto J., and Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med 324 (1991) 933-940
80. Milani S., Schuppan D., Herbst H., and Surrenti C. Expression of transforming growth factor beta, in normal and fibrotic human liver. Molec Cell Biol of Liver Fibrogenesis (1992) 254-262
81. Czaja M.J., Weiner F.R., Flanders K.C., Giambrone M.A., Wind R., Biernpica L., et al. In vitro and in vivo association of TGF beta1 with hepatic fibrosis. J Cell Biol 108 (1989) 2477-2482
82. Nakatsukasa H., Nagy P., Evarts R.P., Hsia C.C., Marsden E., and Thorgeirsson S.S. Cellular distribution of transforming growth factor-beta 1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. J Clin Invest 85 (1990) 1833-1843
83. Bissell D. Hepatic fibrosis as wound repair: a progress report. J Gastroenterol 33 (1998) 295-302
84. Di Rocco P., Grieco A., Bianco A., Caprodossi A., Miele L., Rapaccini G.L., et al. Serum laminin levels in Non Alcoholic Steatohepatitis. J Hepatol 34 suppl 1 (2001) 85
85. Costanzo M., Di Rocco P., Guidi L., Miele L., Giorgi A., Caminiti G., et al. Tumor necrosis factor alpha (TNF-alfa) and transforming growth factor beta (TGF-beta) in nonalcoholic steatohepatitis. Ann Ital Med Int 16 suppl 2 (2001) 55S
86. Costanzo M., Miele L., Forgione A., Di Rocco P., Alfei B., Giorgi A., et al. Metalloproteinases and their inhibitors in nonalcoholic steatohepatitis (NASH). Digest Liver Dis 34 (2002) A53
87. Forgione A., Costanzo M., Miele L., Di Rocco P., Alfei B., Giorgi A., et al. Serum markers of fibrosis in nonalcoholic steatohepatitis (NASH). Gut 51 suppl. 3 (2002) A253
88. Grieco A, Miele L, Forgione A, Diana M, Gasbarrini G. Role of metabolic and nutritional status as risk factors for NASH. Proceedings of 37th ESCI (European Society for Clinical Investigation).
89. Guechot J., Laudat A., Loria A., Serfaty L., Poupon R., and Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 42 (1996) 558-563
90. Tsukamoto T., Yamamoto T., Ikebe T., Takemura S., Shuto T., and Kubo S. Serum markers of liver fibrosis and histologic severity of fibrosis in resected liver. Hepatogastroenterology 51 (2004) 777-780
91. Boeker K.H., Haberkorn C.I., Michels D., Flemming D., Manns M.P., and Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 316 (2002) 71-81
92. Leroy V., Monier F., Bottari S., Trocme C., Sturm N., Hilleret N.H., et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 99 (2004) 271-279
93. Sukugagwa H., Nakayoshi T., Kobashigawa K., Yamashiro T., Maeshiro T., Miyagi S., et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 11 (2005) 255-259
94. Johansen J.S., Christoffersen P., Moller S., Price P.A., Henriksen J.H., Garbarsch C., et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 32 (2000) 911-920
95. Santos V.N., Leite-Mor M.M., Kondo M., Martins J.R., Nader H., Lanzoni V.P., et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 38 (2005) 747-753
96. Lydatakis H., Hager I.P., Kostadelou E., Mpousmpoulas S., Pappas S., Diamantis I., et al. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int 26 (2006) 864-871
97. Sakugawa H., Nakayoshi T., Kobashigawa K., Yamashiro T., Maeshiro T., Miyagi S., et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 11 (2005) 255-259
98. Kaneda H., Hashimoto E., Yatsuji S., Tokushige K., and Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 21 (2006) 1459-1465
99. Suzuki A., Angulo P., Lymp J., Li D., Satomura S., and Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 25 (2005) 779-786
100. Rosenberg W.M., Voelker M., Thiel R., Becka M., Burt A., Schuppan D., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 127 (2004) 1704-1713
101. Poynard T., Ratziu V., Charlotte F., Messous D., Munteanu M., Imbert-Bismut F., et al., LIDO Study Group and the CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6 (2006) 34
102. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., and Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 (2001) 1069-1075
103. Forns X., Ampurdanes S., Llovet J.M., Aponte J., Quinto L., Martinez-Bauer L., et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 36 (2002) 986-992
104. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 (2003) 518-526
105. Poynard T., Imbert-Bismut F., Munteanu M., Messous D., Myers R.P., Thabut D., et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 3 (2004) 8
106. Fontana R.J., and Lok A.S. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 36 (2002) S57-S64
107. Willner I.R., Waters B., Patil S.R., Reuben A., Morelli J., and Riely C.A. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 96 (2001) 2957-2961
108. Valenti L., Fracanzani A.L., Dongiovanni P., Santorelli G., Branchi A., Taioli E., et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122 (2002) 274-280
109. Mensenkamp A.R., Havekes L.M., Romijn J.A., and Kuipers F. Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. J Hepatol 35 (2001) 816-822
110. Bernard S., Touzet S., Personne I., Lapras V., Bondon P.J., Berthezene F., et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia 43 (2000) 995-999
111. Day C.P. Genetic studies to identify hepatic fibrosis genes and SNPs in human populations. Methods Mol Med 117 (2005) 315-331
112. Daly A.K., and Day C.P. Candidate gene case-control association studies: advantages and potential pitfalls. Br J Clin Pharmacol 52 (2001) 489-499
113. Oliver J., Agundez J.A., Morales S., Fernandez-Arquero M., Fernandez-Gutierrez B., de la Concha E.G., et al. Polymorphisms in the transforming growth factor-beta gene (TGF-beta) and the risk of advanced alcoholic liver disease. Liver Int 25 (2005) 935-939
114. Dixon J.B., Bhathal P.S., Jonsson J.R., Dixon A.F., Powell E.E., and O'Brien P.E. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol 39 (2003) 967-971
115. Day C.P. The potential role of genes in nonalcoholic fatty liver disease. Clin Liver Dis 8 (2004) 673-691 xi
116. Hillebrandt S., Goos C., Matern S., and Lammert F. Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology 123 (2002) 2041-2051
117. Hillebrandt S., Wasmuth H.E., Weiskirchen R., Hellerbrand C., Keppeler H., Werth A., et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet 37 (2005) 835-843
118. Lipshutz R.J., Fodor S.P., Gingeras T.R., and Lockhart D.J. High density synthetic oligonucleotide arrays. Nat Genet 21 suppl 1 (1999) 20-24
119. Liu X.J., Yang L., Luo F.M., Wu H.B., and Qiang Q. Association of differentially expressed genes with activation of mouse hepatic stellate cells by high-density cDNA mircoarray. World J Gastroenterol 10 (2004) 1600-1607
120. Younossi Z.M., Gorreta F., Ong J.P., Schlauch K., Del Giacco L., Elariny H., et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int 25 (2005) 760-771
121. Younossi Z.M., Baranova A., Ziegler K., Del Giacco L., Schlauch K., Born T.L., et al. A genomic and proteomic study of the spectrum of Nonalcoholic Fatty Liver Disease. Hepatology 42 (2005) 665-674
122. Sreekumar R., Rosado B., Rasmussen D., and Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 38 (2003) 244-251